Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aceto Strikes Deal To Offload Rising For Just US$15m

Executive Summary

Aceto has struck a deal to sell its Rising Pharmaceuticals unit and related businesses to Shore Suven Pharma for US$15 million. The agreement comes shortly after Aceto agreed to divest its chemicals business assets for US$338 million after filing Chapter 11 bankruptcy petitions in the US.

You may also be interested in...



Rising Bags Private Equity Investment As Parent Suven Pharma Sells Stake

Executive Summary: Through a transaction valued at approximately $56.4m, the private equity giant H.I.G. Capital has acquired Suven Pharma’s 25% stake in Rising Pharma Holdings.

Rogers Becomes Aceto’s President

Steven Rogers has become president of ailing US firm Aceto, in the wake of William Kennally’s termination as president and CEO. Meanwhile, the firm’s chief financial officer has also stepped down.

Aceto 'No Longer Requires' CEO Kennally

Aceto has terminated William Kennally’s tenure as president and CEO of the struggling US firm, following deals struck to divest its Rising Pharmaceuticals generics business and chemicals unit as part of bankruptcy proceedings. Meanwhile, the Nasdaq listing has confirmed that Aceto will be delisted in mid-June.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel